Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27963733 | 0.86 | TSHR (0.55) | PAX8GSK3BTSHRL3MBTL1NAMPT | |
| SCHEMBL4284474 | 0.85 | GRM4 (0.47) | TSHRL3MBTL1SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL4293839 | 0.85 | PAX8 (0.59) | PAX8TSHRNAMPTSMN1; SMN2HTT | |
| SCHEMBL4279916 | 0.84 | GSK3B (0.66) | PAX8GSK3BTSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL5268958 | 0.82 | RAB9A (0.52) | L3MBTL1SMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL4283194 | 0.82 | PAX8 (0.65) | PAX8GSK3BTSHRL3MBTL1NAMPT | |
| SCHEMBL4281573 | 0.81 | L3MBTL1 (0.49) | PAX8GSK3BTSHRL3MBTL1SMN1; SMN2 | |
| SCHEMBL4285745 | 0.81 | GRM5 (0.43) | PAX8GSK3BTSHRL3MBTL1NAMPT | |
| SCHEMBL5267481 | 0.81 | MDM4 (0.49) | SMN1; SMN2HTTALDH1A1HPGDNPC1 | |
| SCHEMBL15062819 | 0.81 | GSK3B (0.71) | PAX8GSK3BTSHRL3MBTL1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1847531-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156582-A1 | Pyrazole Compound | GSK3B, GSK3A, GSKIP | PAX8 3189/4885GSK3B 1/4885TSHR 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.